

[Menu](#)**Cleveland Clinic****Center for Continuing Education**

2016 Pulmonary Hypertension Summit Webcast Series

Pulmonary Arterial Hypertension Diagnosis, Classifications and Therapy

Release Date: June 29, 2016**Expiration Date:** June 29, 2018**Estimated Time of Completion:** 1 hour

Description

[2016 Pulmonary Hypertension Summit Webcast Series](#) reviews pulmonary hypertension diagnosis and treatment, including the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients.

This webcast reviews challenges in the treatment of Pulmonary Arterial Hypertension (PAH) and CTEPH as well as classification scheme and evolution in diagnostic tests for all types of Pulmonary Hypertension. Traditional and novel endpoints in Pulmonary Arterial Hypertension clinical trials will be discussed as well as assets and deficiencies of short-term vs. long-term PAH clinical trials. The webcast will also review upcoming clinical trials evaluating new targets in PAH.

Learning Objectives

1. Review the definition of pulmonary hypertension.
2. Explain the classification scheme of pulmonary hypertension.
3. Discuss the diagnostic algorithm for pulmonary hypertension.
4. Identify traditional and novel endpoints in PAH clinical trials.
5. Compare and contrast the assets and deficiencies of short-term vs long-term PAH clinical trials.
6. Review the primary endpoints used in recent event-driven PAH clinical trials.
7. Discuss upcoming clinical trials evaluating new targets in PAH.

Target Audience

These activities are directed to physicians, physician assistants, and nurses with an interest in

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation

Activity Directors and Faculty

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. The following faculty have indicated that they may have a relationship which, in the context of their contribution, could be perceived as a potential conflict of interest:

Raed A. Dweik, MD

Bayer Healthcare

Consulting, scientific advisory capacity

Gustavo A. Heresi, MD

Bayer Healthcare

Membership on advisory committee or review panels; Teaching and Speaking

United Therapeutics Corporation

Membership on advisory committee or review panels

Kristin Highland, MD

Actelion; Bayer Healthcare; Gilead Sciences; Lung
Biotechnology; United Therapeutics Corporation

Consulting; Teaching and Speaking

Ronald J. Oudiz, MD, FACP, FACC, FCCP

REATA Pharmaceuticals

Payments for enrollment in clinical trials

Franck Rahaghi, MD

Actelion; Bayer Healthcare; Gilead Sciences, Inc.; Lung Rx; Consulting; Teaching and Speaking
United Therapeutics Corporation

The following faculty has indicated that she has no relationship which, in the context of her presentation(s), could be perceived as a potential conflict of interest:

Samar Farha, MD

The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:

**Actelion Pharmaceuticals US, Inc.
Bayer HealthCare Pharmaceuticals
Gilead Sciences, Inc.**

United Therapeutics Corporation and Lung Biotechnologies

Begin Activity

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education and the [Cleveland Clinic Respiratory Institute](#).